Last updated Nov 3, 2026
A 20-year-old presents with hearing loss and tinnitus. MRI reveals bilateral vestibular schwannomas. She also has multiple meningiomas and a spinal ependymoma.
AD; NF2 (merlin, a tumor suppressor); loss of function, about 50% de novo, and 25% to 50% of de novo cases are mosaic. Now also called NF2-related schwannomatosis.
Merlin is a large FERM-domain protein (named for its likeness to moesin, ezrin, and radixin) that coordinates growth factor receptor signaling with cell adhesion. It helps control several signaling pathways (PI3K-AKT, RAC-PAK, EGFR-RAS-ERK) and acts in the Hippo pathway by suppressing YAP and TAZ. How loss of merlin produces this particular tumor spectrum is not fully understood; one proposal is that cell types differ in how much they rely on its organizing role.
The disorder is loss of function, and variant class predicts severity:
- Nonsense and frameshift: severe disease at any position in the gene, with earlier and more numerous meningiomas, spinal tumors, and nerve tumors, and higher mortality.
- Missense: usually the mildest form; the full-length product may keep partial function.
- Large deletions: milder, which nonsense-mediated decay alone does not explain.
- Position: variants in the 3' half (exons 14 to 16) carry a lower meningioma risk.
Mosaicism matters for testing. A mosaic person can test negative in blood, so tumor tissue may be needed, and a severe truncating variant present in only some cells gives a milder course.
- Bilateral vestibular schwannomas (hallmark, typically by age 30)
- Other schwannomas, meningiomas, ependymomas
- Juvenile posterior subcapsular cataracts
- Few if any café-au-lait spots
vs NF1: NF2 = tumors of nervous system, NF1 = café-au-lait + neurofibromas
- Diagnostic with bilateral vestibular schwannomas, or an affected first-degree relative plus a unilateral vestibular schwannoma or two other characteristic tumors (schwannoma, meningioma, ependymoma)
- Gadolinium-enhanced brain MRI (internal auditory canals) is the key imaging study; audiometry for hearing assessment
- Molecular testing of NF2 confirms the diagnosis and enables family/prenatal testing; note frequent mosaicism, which can lower blood-test detection
- Slit-lamp exam for juvenile posterior subcapsular cataracts
- Serial brain and spine MRI plus annual audiology to monitor tumor growth and hearing
- Bevacizumab can shrink vestibular schwannomas and improve hearing in selected patients
- Surgery or stereotactic radiosurgery for symptomatic or growing tumors; hearing preservation and auditory brainstem implants when indicated
- Manage at a multidisciplinary specialty center; genetic counseling for autosomal dominant inheritance
"NF2 = 2 eyes, 2 ears": Bilateral vestibular schwannomas (hearing loss) and posterior subcapsular cataracts (visual loss). "NF 2 has catworacts."
"Skin spots Twinkle (very light/hypopigmented) in NF type Two": NF2 may have a few hypopigmented cafe-au-lait spots (vs hyperpigmented in NF1), but not as many as NF1.
NF2 on chr 22: NF2 encodes merlin (schwannomin), a tumor suppressor on chromosome 22.